 Ernesto Sparrelid
Concepts (396)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatectomy | 50 | 2025 | 205 | 8.510 |
Why?
| | Liver Neoplasms | 42 | 2024 | 637 | 8.480 |
Why?
| | Liver Failure | 14 | 2025 | 90 | 5.190 |
Why?
| | Portal Vein | 24 | 2025 | 106 | 5.140 |
Why?
| | Pancreatic Neoplasms | 22 | 2025 | 878 | 4.740 |
Why?
| | Bile Duct Neoplasms | 17 | 2024 | 99 | 4.570 |
Why?
| | Pancreatectomy | 22 | 2025 | 245 | 3.680 |
Why?
| | Cholangiocarcinoma | 13 | 2024 | 76 | 3.670 |
Why?
| | Carcinoma, Pancreatic Ductal | 9 | 2025 | 264 | 3.270 |
Why?
| | Adenocarcinoma, Mucinous | 4 | 2022 | 72 | 2.950 |
Why?
| | Colorectal Neoplasms | 17 | 2022 | 730 | 2.810 |
Why?
| | Liver | 22 | 2025 | 1832 | 2.380 |
Why?
| | Embolization, Therapeutic | 6 | 2024 | 209 | 2.290 |
Why?
| | Carcinoma, Hepatocellular | 8 | 2024 | 267 | 1.920 |
Why?
| | Klatskin Tumor | 10 | 2024 | 14 | 1.850 |
Why?
| | Liver Regeneration | 7 | 2024 | 39 | 1.820 |
Why?
| | Pancreaticoduodenectomy | 10 | 2024 | 159 | 1.620 |
Why?
| | Adenocarcinoma, Papillary | 2 | 2022 | 11 | 1.610 |
Why?
| | Postoperative Complications | 31 | 2025 | 2494 | 1.420 |
Why?
| | Retrospective Studies | 61 | 2025 | 14546 | 1.410 |
Why?
| | Bile Ducts, Intrahepatic | 7 | 2024 | 65 | 1.400 |
Why?
| | Biliary Tract Surgical Procedures | 4 | 2025 | 25 | 1.340 |
Why?
| | Biliary Tract Neoplasms | 3 | 2023 | 25 | 1.150 |
Why?
| | Pancreatic Fistula | 6 | 2025 | 26 | 1.110 |
Why?
| | Neoadjuvant Therapy | 7 | 2025 | 383 | 1.080 |
Why?
| | Bone Marrow Transplantation | 15 | 2000 | 267 | 1.020 |
Why?
| | Aged | 49 | 2025 | 22035 | 1.000 |
Why?
| | Humans | 130 | 2025 | 128896 | 0.960 |
Why?
| | Cysts | 1 | 2025 | 108 | 0.890 |
Why?
| | Middle Aged | 55 | 2025 | 30977 | 0.890 |
Why?
| | Gallbladder Neoplasms | 2 | 2023 | 21 | 0.880 |
Why?
| | Ligation | 12 | 2021 | 87 | 0.870 |
Why?
| | Prognosis | 17 | 2025 | 3787 | 0.850 |
Why?
| | Liver Diseases | 3 | 2025 | 284 | 0.820 |
Why?
| | Sweden | 11 | 2025 | 92 | 0.720 |
Why?
| | Metastasectomy | 1 | 2021 | 21 | 0.720 |
Why?
| | Fellowships and Scholarships | 1 | 2024 | 271 | 0.700 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2025 | 1570 | 0.670 |
Why?
| | Robotic Surgical Procedures | 4 | 2025 | 108 | 0.660 |
Why?
| | Adult | 44 | 2025 | 35361 | 0.650 |
Why?
| | Tomography, X-Ray Computed | 5 | 2025 | 2530 | 0.640 |
Why?
| | Carcinoma | 1 | 2021 | 214 | 0.630 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2021 | 170 | 0.620 |
Why?
| | Male | 55 | 2025 | 63146 | 0.600 |
Why?
| | Liver Function Tests | 4 | 2022 | 110 | 0.570 |
Why?
| | Female | 54 | 2025 | 68162 | 0.560 |
Why?
| | Stem Cell Transplantation | 2 | 2015 | 167 | 0.530 |
Why?
| | Laparoscopy | 4 | 2024 | 452 | 0.520 |
Why?
| | Hepatitis B virus | 1 | 2016 | 34 | 0.510 |
Why?
| | Adenoviridae Infections | 1 | 2015 | 16 | 0.500 |
Why?
| | Liver Transplantation | 3 | 2021 | 800 | 0.500 |
Why?
| | Patient Acceptance of Health Care | 1 | 2021 | 764 | 0.490 |
Why?
| | Adenoviridae | 1 | 2015 | 193 | 0.470 |
Why?
| | Health Services Accessibility | 1 | 2021 | 894 | 0.460 |
Why?
| | Survival Rate | 12 | 2025 | 1884 | 0.460 |
Why?
| | Risk Factors | 19 | 2025 | 9792 | 0.450 |
Why?
| | Hypertrophy | 3 | 2024 | 120 | 0.440 |
Why?
| | Practice Patterns, Physicians' | 2 | 2024 | 1281 | 0.440 |
Why?
| | Pancreatitis, Chronic | 2 | 2024 | 51 | 0.440 |
Why?
| | Prospective Studies | 11 | 2025 | 7060 | 0.430 |
Why?
| | Lymph Nodes | 5 | 2024 | 458 | 0.430 |
Why?
| | Lymphatic Metastasis | 2 | 2024 | 312 | 0.420 |
Why?
| | Adenocarcinoma | 3 | 2024 | 895 | 0.420 |
Why?
| | Disease Outbreaks | 1 | 2015 | 333 | 0.400 |
Why?
| | Aged, 80 and over | 12 | 2025 | 7050 | 0.400 |
Why?
| | Leucovorin | 5 | 2025 | 69 | 0.390 |
Why?
| | Organ Size | 3 | 2024 | 446 | 0.380 |
Why?
| | Pancreatitis | 2 | 2022 | 129 | 0.370 |
Why?
| | Margins of Excision | 3 | 2021 | 38 | 0.360 |
Why?
| | Serum Albumin | 2 | 2022 | 145 | 0.350 |
Why?
| | Cholangitis, Sclerosing | 2 | 2021 | 68 | 0.350 |
Why?
| | Scandinavian and Nordic Countries | 4 | 2024 | 12 | 0.350 |
Why?
| | Follow-Up Studies | 10 | 2025 | 4917 | 0.350 |
Why?
| | Magnetic Resonance Imaging | 6 | 2025 | 3348 | 0.340 |
Why?
| | Biliary Tract | 2 | 2021 | 15 | 0.330 |
Why?
| | Fluorouracil | 4 | 2025 | 198 | 0.330 |
Why?
| | Neoplasm Staging | 4 | 2024 | 1285 | 0.330 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2025 | 952 | 0.290 |
Why?
| | Radionuclide Imaging | 3 | 2022 | 126 | 0.280 |
Why?
| | Treatment Outcome | 16 | 2025 | 10239 | 0.280 |
Why?
| | Intention to Treat Analysis | 2 | 2024 | 72 | 0.280 |
Why?
| | Contrast Media | 4 | 2025 | 387 | 0.270 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2024 | 83 | 0.270 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2024 | 824 | 0.270 |
Why?
| | Indocyanine Green | 2 | 2023 | 17 | 0.260 |
Why?
| | T-Lymphocyte Subsets | 3 | 2024 | 410 | 0.260 |
Why?
| | Lymph Node Excision | 2 | 2024 | 166 | 0.260 |
Why?
| | Transplantation, Autologous | 4 | 2023 | 214 | 0.260 |
Why?
| | Bacteremia | 5 | 2013 | 190 | 0.250 |
Why?
| | Survival Analysis | 5 | 2021 | 1282 | 0.250 |
Why?
| | Quinolines | 2 | 2024 | 149 | 0.250 |
Why?
| | Digestive System Surgical Procedures | 2 | 2024 | 96 | 0.250 |
Why?
| | Propensity Score | 2 | 2024 | 262 | 0.240 |
Why?
| | Gallbladder Diseases | 1 | 2024 | 9 | 0.240 |
Why?
| | Liver Cirrhosis | 2 | 2024 | 274 | 0.240 |
Why?
| | Failure to Rescue, Health Care | 1 | 2024 | 3 | 0.240 |
Why?
| | Mesenteric Veins | 1 | 2025 | 19 | 0.240 |
Why?
| | CA-19-9 Antigen | 1 | 2024 | 23 | 0.230 |
Why?
| | Operative Time | 1 | 2024 | 120 | 0.230 |
Why?
| | Blood Loss, Surgical | 1 | 2024 | 91 | 0.220 |
Why?
| | Duodenal Neoplasms | 1 | 2024 | 22 | 0.220 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2024 | 27 | 0.220 |
Why?
| | Ampulla of Vater | 1 | 2024 | 39 | 0.220 |
Why?
| | Pancreas | 5 | 2024 | 307 | 0.220 |
Why?
| | Registries | 4 | 2024 | 1916 | 0.210 |
Why?
| | Cholangitis | 1 | 2023 | 20 | 0.210 |
Why?
| | Patient Outcome Assessment | 1 | 2024 | 128 | 0.210 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2023 | 59 | 0.210 |
Why?
| | Warfare | 1 | 2023 | 63 | 0.210 |
Why?
| | Hyperemia | 1 | 2023 | 48 | 0.210 |
Why?
| | Delphi Technique | 1 | 2024 | 219 | 0.210 |
Why?
| | Exocrine Pancreatic Insufficiency | 1 | 2022 | 20 | 0.210 |
Why?
| | Antiviral Agents | 4 | 2015 | 708 | 0.200 |
Why?
| | alpha 1-Antitrypsin Deficiency | 1 | 2023 | 71 | 0.200 |
Why?
| | Carcinoma, Papillary | 1 | 2023 | 77 | 0.200 |
Why?
| | Stomach Neoplasms | 1 | 2023 | 97 | 0.200 |
Why?
| | Hemostatics | 1 | 2022 | 47 | 0.200 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2021 | 22 | 0.190 |
Why?
| | alpha 1-Antitrypsin | 1 | 2023 | 111 | 0.190 |
Why?
| | Fibrinogen | 1 | 2022 | 159 | 0.190 |
Why?
| | Hepatic Veins | 2 | 2022 | 31 | 0.190 |
Why?
| | Mucosal-Associated Invariant T Cells | 1 | 2021 | 27 | 0.190 |
Why?
| | DNA, Viral | 3 | 2015 | 380 | 0.180 |
Why?
| | Pancreatic Cyst | 1 | 2021 | 53 | 0.180 |
Why?
| | Ablation Techniques | 1 | 2021 | 31 | 0.180 |
Why?
| | Multivariate Analysis | 4 | 2019 | 1504 | 0.180 |
Why?
| | Mycoses | 2 | 1998 | 70 | 0.180 |
Why?
| | Intraoperative Care | 1 | 2020 | 44 | 0.180 |
Why?
| | Camptothecin | 1 | 2021 | 106 | 0.170 |
Why?
| | Bevacizumab | 1 | 2021 | 130 | 0.170 |
Why?
| | Transplantation, Homologous | 8 | 2013 | 403 | 0.170 |
Why?
| | Sarcopenia | 1 | 2021 | 73 | 0.170 |
Why?
| | Cytomegalovirus Infections | 4 | 1998 | 190 | 0.170 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2024 | 739 | 0.170 |
Why?
| | Precancerous Conditions | 1 | 2021 | 164 | 0.170 |
Why?
| | Kaplan-Meier Estimate | 2 | 2019 | 861 | 0.170 |
Why?
| | Incidence | 8 | 2024 | 2634 | 0.170 |
Why?
| | Education, Medical, Graduate | 1 | 2024 | 436 | 0.160 |
Why?
| | Time Factors | 8 | 2024 | 6568 | 0.160 |
Why?
| | Neutropenia | 2 | 2013 | 135 | 0.160 |
Why?
| | Bacterial Infections | 2 | 1998 | 236 | 0.160 |
Why?
| | Neoplasm Grading | 1 | 2019 | 277 | 0.160 |
Why?
| | Adipose Tissue | 1 | 2022 | 588 | 0.150 |
Why?
| | Receptors, KIR | 1 | 2019 | 96 | 0.150 |
Why?
| | Hepatocyte Growth Factor | 1 | 2018 | 34 | 0.150 |
Why?
| | Neoplasm Invasiveness | 1 | 2019 | 479 | 0.150 |
Why?
| | Autoimmune Diseases | 1 | 2021 | 419 | 0.150 |
Why?
| | Atrial Fibrillation | 1 | 2022 | 370 | 0.150 |
Why?
| | Europe | 3 | 2024 | 366 | 0.150 |
Why?
| | HLA Antigens | 1 | 2019 | 236 | 0.140 |
Why?
| | Epidermal Growth Factor | 1 | 2018 | 170 | 0.140 |
Why?
| | Catheter Ablation | 1 | 2021 | 324 | 0.140 |
Why?
| | Parainfluenza Virus 1, Human | 1 | 1997 | 3 | 0.140 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2023 | 561 | 0.140 |
Why?
| | Respirovirus Infections | 1 | 1997 | 23 | 0.140 |
Why?
| | C-Reactive Protein | 1 | 2019 | 394 | 0.140 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 203 | 0.140 |
Why?
| | Thyrotropin | 3 | 2021 | 109 | 0.140 |
Why?
| | Influenza B virus | 1 | 1997 | 37 | 0.140 |
Why?
| | Curriculum | 1 | 2024 | 925 | 0.140 |
Why?
| | Th2 Cells | 2 | 1997 | 169 | 0.140 |
Why?
| | Constriction, Pathologic | 1 | 2017 | 230 | 0.140 |
Why?
| | Graft Survival | 3 | 1998 | 523 | 0.140 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2025 | 380 | 0.140 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 1997 | 166 | 0.130 |
Why?
| | Virus Diseases | 2 | 2016 | 207 | 0.130 |
Why?
| | Clinical Competence | 1 | 2024 | 1020 | 0.130 |
Why?
| | Multicenter Studies as Topic | 3 | 2022 | 287 | 0.130 |
Why?
| | Ribavirin | 1 | 1997 | 92 | 0.130 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1221 | 0.130 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1523 | 0.130 |
Why?
| | Postoperative Period | 3 | 2023 | 319 | 0.130 |
Why?
| | Cytokines | 3 | 2004 | 1995 | 0.130 |
Why?
| | Killer Cells, Natural | 1 | 2019 | 422 | 0.130 |
Why?
| | Logistic Models | 1 | 2021 | 1963 | 0.130 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 1997 | 117 | 0.120 |
Why?
| | Cytosine | 1 | 2015 | 46 | 0.120 |
Why?
| | Hepatitis B | 1 | 2016 | 61 | 0.120 |
Why?
| | Treatment Failure | 1 | 2016 | 345 | 0.120 |
Why?
| | Gaucher Disease | 1 | 1995 | 6 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2018 | 528 | 0.120 |
Why?
| | Inflammation | 2 | 2022 | 2694 | 0.120 |
Why?
| | Organophosphonates | 1 | 2015 | 91 | 0.120 |
Why?
| | Acute Kidney Injury | 1 | 2023 | 786 | 0.120 |
Why?
| | Interleukin-6 | 2 | 2018 | 715 | 0.120 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2015 | 48 | 0.120 |
Why?
| | Sepsis | 2 | 2004 | 561 | 0.120 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 5355 | 0.120 |
Why?
| | Opportunistic Infections | 1 | 1995 | 46 | 0.120 |
Why?
| | Japan | 2 | 2025 | 100 | 0.110 |
Why?
| | Insulin Resistance | 1 | 2022 | 1163 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 991 | 0.110 |
Why?
| | Fungemia | 1 | 2013 | 4 | 0.110 |
Why?
| | Quality of Life | 5 | 2024 | 2706 | 0.110 |
Why?
| | Reoperation | 1 | 2016 | 555 | 0.110 |
Why?
| | Cholecystectomy | 2 | 2024 | 60 | 0.110 |
Why?
| | Gadolinium DTPA | 2 | 2025 | 49 | 0.110 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2013 | 576 | 0.110 |
Why?
| | Graft Rejection | 1 | 1997 | 566 | 0.110 |
Why?
| | Bile Ducts | 2 | 2024 | 66 | 0.110 |
Why?
| | Graft vs Host Disease | 8 | 2000 | 238 | 0.100 |
Why?
| | Pandemics | 1 | 2021 | 1516 | 0.100 |
Why?
| | Immunosuppressive Agents | 1 | 1997 | 699 | 0.100 |
Why?
| | Phenotype | 4 | 2024 | 3059 | 0.100 |
Why?
| | Child, Preschool | 12 | 2013 | 10457 | 0.100 |
Why?
| | Phylogeny | 1 | 2015 | 843 | 0.090 |
Why?
| | Risk Assessment | 3 | 2025 | 3286 | 0.090 |
Why?
| | Lung Diseases, Interstitial | 1 | 1997 | 594 | 0.090 |
Why?
| | Influenza, Human | 1 | 1997 | 603 | 0.090 |
Why?
| | RNA, Messenger | 1 | 2018 | 2700 | 0.090 |
Why?
| | Viridans Streptococci | 2 | 2013 | 6 | 0.080 |
Why?
| | Obesity | 1 | 2022 | 2844 | 0.080 |
Why?
| | Tumor Microenvironment | 2 | 2024 | 588 | 0.080 |
Why?
| | Heart Failure | 1 | 2022 | 2142 | 0.080 |
Why?
| | Lymphoproliferative Disorders | 1 | 2009 | 53 | 0.080 |
Why?
| | Herpesvirus 4, Human | 1 | 2009 | 153 | 0.070 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5032 | 0.070 |
Why?
| | Leukemia | 4 | 1998 | 228 | 0.070 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2009 | 93 | 0.070 |
Why?
| | Anti-Infective Agents | 3 | 2013 | 246 | 0.070 |
Why?
| | Polymerase Chain Reaction | 2 | 2009 | 1045 | 0.070 |
Why?
| | Tumor Burden | 2 | 2021 | 284 | 0.070 |
Why?
| | Cohort Studies | 3 | 2024 | 5394 | 0.070 |
Why?
| | Infant | 8 | 2013 | 8994 | 0.070 |
Why?
| | Hematologic Diseases | 2 | 1998 | 61 | 0.070 |
Why?
| | T-Lymphocytes | 3 | 2021 | 1905 | 0.070 |
Why?
| | Norway | 2 | 2016 | 42 | 0.060 |
Why?
| | Child | 11 | 2013 | 20824 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 1366 | 0.060 |
Why?
| | Conversion to Open Surgery | 1 | 2025 | 15 | 0.060 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 608 | 0.060 |
Why?
| | Histocompatibility Testing | 4 | 1998 | 122 | 0.060 |
Why?
| | Albumins | 1 | 2025 | 102 | 0.060 |
Why?
| | Preoperative Period | 1 | 2024 | 112 | 0.060 |
Why?
| | Adolescent | 10 | 2022 | 20197 | 0.060 |
Why?
| | Capecitabine | 1 | 2024 | 48 | 0.060 |
Why?
| | Israel | 1 | 2023 | 47 | 0.060 |
Why?
| | Lactates | 1 | 2024 | 83 | 0.050 |
Why?
| | Deoxycytidine | 1 | 2025 | 163 | 0.050 |
Why?
| | Paclitaxel | 1 | 2025 | 214 | 0.050 |
Why?
| | Gallium Radioisotopes | 1 | 2023 | 14 | 0.050 |
Why?
| | Bilirubin | 1 | 2024 | 91 | 0.050 |
Why?
| | Amphotericin B | 2 | 2013 | 29 | 0.050 |
Why?
| | Medical Futility | 1 | 2023 | 24 | 0.050 |
Why?
| | ROC Curve | 1 | 2025 | 500 | 0.050 |
Why?
| | Keratin-19 | 1 | 2023 | 3 | 0.050 |
Why?
| | Candidiasis | 2 | 2013 | 57 | 0.050 |
Why?
| | Rare Diseases | 1 | 2024 | 102 | 0.050 |
Why?
| | Amylases | 1 | 2022 | 16 | 0.050 |
Why?
| | Time-to-Treatment | 1 | 2024 | 182 | 0.050 |
Why?
| | Hepatomegaly | 1 | 2022 | 5 | 0.050 |
Why?
| | Gastrectomy | 1 | 2023 | 99 | 0.050 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2023 | 127 | 0.050 |
Why?
| | Hepatocytes | 1 | 2023 | 215 | 0.050 |
Why?
| | Accreditation | 1 | 2022 | 81 | 0.050 |
Why?
| | Pancreaticojejunostomy | 1 | 2022 | 7 | 0.050 |
Why?
| | Acute Disease | 2 | 2022 | 978 | 0.050 |
Why?
| | Abdomen | 1 | 2022 | 116 | 0.050 |
Why?
| | Ceramides | 1 | 2022 | 112 | 0.050 |
Why?
| | Regression Analysis | 1 | 2024 | 987 | 0.050 |
Why?
| | Vascular Surgical Procedures | 1 | 2025 | 295 | 0.050 |
Why?
| | Bismuth | 1 | 2021 | 1 | 0.050 |
Why?
| | Endoscopy | 1 | 2024 | 268 | 0.050 |
Why?
| | Anemia, Aplastic | 3 | 1997 | 33 | 0.050 |
Why?
| | Consensus | 1 | 2024 | 644 | 0.050 |
Why?
| | Morbidity | 1 | 2022 | 301 | 0.050 |
Why?
| | Drainage | 1 | 2022 | 162 | 0.050 |
Why?
| | Population Surveillance | 1 | 2024 | 428 | 0.050 |
Why?
| | Neutrophils | 3 | 2021 | 1203 | 0.040 |
Why?
| | Clone Cells | 1 | 2020 | 257 | 0.040 |
Why?
| | Autophagy | 1 | 2022 | 263 | 0.040 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2020 | 214 | 0.040 |
Why?
| | Macaca mulatta | 1 | 2020 | 153 | 0.040 |
Why?
| | Secondary Prevention | 1 | 2021 | 238 | 0.040 |
Why?
| | Cytomegalovirus | 2 | 1997 | 156 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2023 | 684 | 0.040 |
Why?
| | Receptors, KIR2DL3 | 1 | 2019 | 9 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2025 | 727 | 0.040 |
Why?
| | Asia | 1 | 2019 | 58 | 0.040 |
Why?
| | South America | 1 | 2019 | 56 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2024 | 1967 | 0.040 |
Why?
| | Linkage Disequilibrium | 1 | 2019 | 255 | 0.040 |
Why?
| | HLA-A Antigens | 1 | 1998 | 53 | 0.040 |
Why?
| | Immunologic Memory | 1 | 2020 | 335 | 0.040 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 1998 | 56 | 0.040 |
Why?
| | North America | 1 | 2019 | 289 | 0.040 |
Why?
| | HLA-B Antigens | 1 | 1998 | 62 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 2 | 2004 | 543 | 0.040 |
Why?
| | Aspirin | 1 | 2021 | 379 | 0.040 |
Why?
| | Palliative Care | 1 | 2024 | 712 | 0.040 |
Why?
| | Hepatitis, Viral, Human | 1 | 1997 | 25 | 0.040 |
Why?
| | Preoperative Care | 1 | 2020 | 343 | 0.040 |
Why?
| | Viral Matrix Proteins | 1 | 1997 | 25 | 0.040 |
Why?
| | HLA-DR Antigens | 1 | 1998 | 226 | 0.040 |
Why?
| | Iatrogenic Disease | 1 | 2017 | 57 | 0.040 |
Why?
| | Patients | 1 | 2019 | 167 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1435 | 0.040 |
Why?
| | Genetic Association Studies | 1 | 2019 | 356 | 0.040 |
Why?
| | Pilot Projects | 1 | 2022 | 1545 | 0.040 |
Why?
| | Metabolic Diseases | 2 | 1995 | 106 | 0.030 |
Why?
| | Transplantation Conditioning | 1 | 1998 | 166 | 0.030 |
Why?
| | Ligands | 1 | 2019 | 614 | 0.030 |
Why?
| | Liver Failure, Acute | 1 | 1997 | 62 | 0.030 |
Why?
| | Injections, Intravenous | 1 | 1997 | 200 | 0.030 |
Why?
| | Young Adult | 3 | 2024 | 12286 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2021 | 1858 | 0.030 |
Why?
| | Ethanol | 1 | 2021 | 577 | 0.030 |
Why?
| | Prevalence | 1 | 2023 | 2540 | 0.030 |
Why?
| | Antigens, Viral | 1 | 1997 | 181 | 0.030 |
Why?
| | Eye Neoplasms | 1 | 2016 | 17 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 613 | 0.030 |
Why?
| | Qualitative Research | 1 | 2022 | 1192 | 0.030 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2017 | 204 | 0.030 |
Why?
| | Immunoglobulins, Intravenous | 1 | 1996 | 131 | 0.030 |
Why?
| | 4-Quinolones | 1 | 1995 | 2 | 0.030 |
Why?
| | Tomography | 1 | 1995 | 23 | 0.030 |
Why?
| | Phosphoproteins | 1 | 1997 | 326 | 0.030 |
Why?
| | Splenectomy | 1 | 1995 | 59 | 0.030 |
Why?
| | Wilms Tumor | 1 | 2016 | 77 | 0.030 |
Why?
| | Administration, Oral | 1 | 1997 | 783 | 0.030 |
Why?
| | Transcriptome | 1 | 2020 | 871 | 0.030 |
Why?
| | Anthropometry | 1 | 1995 | 205 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2020 | 1408 | 0.030 |
Why?
| | Fluconazole | 1 | 2013 | 18 | 0.030 |
Why?
| | Enterococcus | 1 | 2013 | 24 | 0.030 |
Why?
| | Ciprofloxacin | 1 | 2013 | 30 | 0.030 |
Why?
| | Muscle, Skeletal | 1 | 2023 | 1629 | 0.030 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2013 | 44 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2020 | 1854 | 0.030 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2013 | 67 | 0.030 |
Why?
| | Monocytes | 1 | 1996 | 553 | 0.030 |
Why?
| | Spleen | 1 | 1995 | 518 | 0.030 |
Why?
| | Hepatitis C | 1 | 1995 | 234 | 0.030 |
Why?
| | Patient Safety | 1 | 2016 | 292 | 0.030 |
Why?
| | Linear Models | 1 | 2015 | 817 | 0.020 |
Why?
| | Radiography | 1 | 1995 | 863 | 0.020 |
Why?
| | Delivery of Health Care | 1 | 2019 | 896 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2015 | 859 | 0.020 |
Why?
| | Streptococcal Infections | 1 | 2013 | 145 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3334 | 0.020 |
Why?
| | Biomarkers | 1 | 2023 | 3874 | 0.020 |
Why?
| | Antibodies, Monoclonal | 3 | 2009 | 1359 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2270 | 0.020 |
Why?
| | Animals | 2 | 2023 | 34628 | 0.020 |
Why?
| | Bacterial Proteins | 1 | 1996 | 829 | 0.020 |
Why?
| | Membrane Proteins | 1 | 1996 | 1100 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 85 | 0.020 |
Why?
| | Staphylococcal Infections | 1 | 2013 | 385 | 0.020 |
Why?
| | Melanoma | 1 | 2016 | 735 | 0.020 |
Why?
| | Foscarnet | 2 | 1998 | 20 | 0.020 |
Why?
| | Macrophages | 1 | 1996 | 1452 | 0.020 |
Why?
| | Rituximab | 1 | 2009 | 161 | 0.020 |
Why?
| | Apoptosis | 1 | 1997 | 2481 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2015 | 2337 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2603 | 0.020 |
Why?
| | Viral Load | 1 | 2009 | 448 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2009 | 227 | 0.020 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 1998 | 110 | 0.020 |
Why?
| | Bone Marrow | 2 | 1998 | 262 | 0.020 |
Why?
| | Tissue Donors | 2 | 2000 | 398 | 0.020 |
Why?
| | Mice | 1 | 2023 | 16543 | 0.020 |
Why?
| | Interleukin-1 | 2 | 2004 | 972 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2004 | 261 | 0.010 |
Why?
| | Cells, Cultured | 2 | 2004 | 4048 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2000 | 48 | 0.010 |
Why?
| | alpha-Fetoproteins | 1 | 2000 | 39 | 0.010 |
Why?
| | Age Factors | 2 | 1998 | 3133 | 0.010 |
Why?
| | Transplantation Chimera | 1 | 2000 | 54 | 0.010 |
Why?
| | Whole-Body Irradiation | 1 | 2000 | 76 | 0.010 |
Why?
| | Tissue and Organ Harvesting | 1 | 2000 | 75 | 0.010 |
Why?
| | Cadaver | 1 | 2000 | 332 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2004 | 1204 | 0.010 |
Why?
| | Transplantation Immunology | 1 | 1998 | 33 | 0.010 |
Why?
| | Acyclovir | 1 | 1998 | 104 | 0.010 |
Why?
| | Ganciclovir | 1 | 1997 | 51 | 0.010 |
Why?
| | Leukemia, Myeloid | 1 | 1997 | 44 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2000 | 1213 | 0.010 |
Why?
| | Leukocyte Count | 1 | 1997 | 328 | 0.010 |
Why?
| | Disease-Free Survival | 1 | 1998 | 657 | 0.010 |
Why?
| | Probability | 1 | 1997 | 313 | 0.010 |
Why?
| | Exotoxins | 1 | 1996 | 15 | 0.010 |
Why?
| | Streptococcus | 1 | 1996 | 25 | 0.010 |
Why?
| | Lymphokines | 1 | 1996 | 126 | 0.010 |
Why?
| | CD3 Complex | 1 | 1996 | 99 | 0.010 |
Why?
| | Sialoglycoproteins | 1 | 1996 | 155 | 0.010 |
Why?
| | Th1 Cells | 1 | 1996 | 135 | 0.010 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 1996 | 252 | 0.010 |
Why?
| | Blood Platelets | 1 | 1998 | 369 | 0.010 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1997 | 282 | 0.010 |
Why?
| | Anemia | 1 | 1995 | 155 | 0.010 |
Why?
| | Biopsy | 1 | 1997 | 1093 | 0.010 |
Why?
| | Down-Regulation | 1 | 1996 | 637 | 0.010 |
Why?
| | Lipopolysaccharides | 1 | 1996 | 877 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 1996 | 1091 | 0.010 |
Why?
| | Liposomes | 1 | 1993 | 163 | 0.010 |
Why?
| | Neoplasms | 1 | 1993 | 2426 | 0.000 |
Why?
|
|
Sparrelid's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|